Inventiva S.A (IVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inventiva S.A (IVA) has a cash flow conversion efficiency ratio of 5.765x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-53.89 Million ≈ $-63.01 Million USD) by net assets (€-9.35 Million ≈ $-10.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Inventiva S.A - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Inventiva S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read IVA total debt and obligations for a breakdown of total debt and financial obligations.
Inventiva S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inventiva S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hana Microelectronics Public Company Limited
BK:HANA
|
0.030x |
|
Tianjin Tianyao Pharmaceuticals Co Ltd
SHG:600488
|
0.003x |
|
Hangzhou Fortune Gas Cryogenic Group Co. Ltd. A
SHG:603173
|
N/A |
|
InMode Ltd
NASDAQ:INMD
|
0.033x |
|
Sedlmayr Grund und Immobilien AG
F:SPB
|
N/A |
|
INVEX Controladora S.A.B. de C.V
MX:INVEXA
|
0.059x |
|
Hangzhou Huning Elevator Parts Co Ltd
SHE:300669
|
0.008x |
|
Horizon Bancorp
NASDAQ:HBNC
|
0.016x |
Annual Cash Flow Conversion Efficiency for Inventiva S.A (2013–2024)
The table below shows the annual cash flow conversion efficiency of Inventiva S.A from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Inventiva S.A.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-106.65 Million ≈ $-124.68 Million |
€-85.93 Million ≈ $-100.46 Million |
0.806x | -68.38% |
| 2023-12-31 | €-32.03 Million ≈ $-37.45 Million |
€-81.61 Million ≈ $-95.42 Million |
2.548x | +357.90% |
| 2022-12-31 | €45.48 Million ≈ $53.17 Million |
€-44.93 Million ≈ $-52.53 Million |
-0.988x | -84.33% |
| 2021-12-31 | €88.87 Million ≈ $103.89 Million |
€-47.63 Million ≈ $-55.68 Million |
-0.536x | -94.85% |
| 2020-12-31 | €111.21 Million ≈ $130.02 Million |
€-30.59 Million ≈ $-35.76 Million |
-0.275x | +59.92% |
| 2019-12-31 | €41.39 Million ≈ $48.39 Million |
€-28.40 Million ≈ $-33.21 Million |
-0.686x | -23.57% |
| 2018-12-31 | €61.60 Million ≈ $72.01 Million |
€-34.21 Million ≈ $-39.99 Million |
-0.555x | -109.07% |
| 2017-12-31 | €64.01 Million ≈ $74.83 Million |
€-17.00 Million ≈ $-19.88 Million |
-0.266x | +36.15% |
| 2016-12-31 | €35.72 Million ≈ $41.76 Million |
€-14.86 Million ≈ $-17.37 Million |
-0.416x | -27.24% |
| 2015-12-31 | €42.77 Million ≈ $50.00 Million |
€-13.98 Million ≈ $-16.35 Million |
-0.327x | -13.88% |
| 2014-12-31 | €51.51 Million ≈ $60.22 Million |
€-14.79 Million ≈ $-17.29 Million |
-0.287x | -5.83% |
| 2013-12-31 | €59.01 Million ≈ $68.99 Million |
€-16.01 Million ≈ $-18.72 Million |
-0.271x | -- |
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more